Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

New fungicidal seed treatment product for oilseed rape:

First approval worldwide for EverGol™ in seed treatment

Launch in Canada planned before the end of the year

Leverkusen, Germany, April 20, 2012 – Bayer CropScience has been granted the first regulatory approval worldwide for its new fungicidal seed treatment solution EverGol™ (active ingredient: penflufen) in Canada. The product sets a new standard in the control of *Rhizoctonia solani,* the most important disease in the Canadian canola, a summer oilseed rape crop. Products based on EverGol™ are characterized by a comprehensive and complete spectrum of activity. Canola seed treated with EverGol™ produces a healthy, vital canola crop and accordingly provides ideal conditions for increasing the marketable yield. It is planned to launch EverGol™ in Canada before the end of 2012.

"The registration of EverGol™ underlines our role as a leading provider of crop protection agents and seed in the oilseed rape business," said Matthias Haug, who is responsible for the global Seed Treatment business at Bayer CropScience. Last year, Bayer announced the registration of Emesto™, a seed treatment product for potatoes with the same active ingredient, in the United Kingdom. Products from the EverGol™/Emesto™ family are expected to be granted approval in more than 40 countries globally including the growing markets for seed treatment compounds in Latin America and Asia.

Bayer CropScience is developing customer-oriented solutions on the basis of EverGol™/ Emesto™ brand family for other economically significant crops beyond canola such as potatoes, soybeans, corn, cereals, cotton, rice and pulses. The market launches for these products are scheduled for 2012 onwards.

The active crop protection ingredient penflufen belongs to a new generation of SDH (succinate dehydrogenase) inhibitors. Products based on this innovative substance strengthen roots as well as entire plants during the delicate juvenile development phase

and thus ensure consistent emergence and improved establishment in a wide spectrum of crops. They offer farmers markedly better options for stemming the main seed- and soil-borne diseases such as Rhizoctonia-, Fusarium- and Pythium-rots as well as Helminthosporium, even at very low application volumes. All products based on penflufen provide outstanding crop tolerance. They also help to drive yields and quality compared to existing seed treatment solutions. Therefore these new products make an important contribution throughout the entire value-added chain.

About Bayer CropScience

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience, a subgroup of Bayer AG with annual sales of EUR 7.255 billion (2011), is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 21,000 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)
Ute Menke (+49-214-30-33021)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual financial position, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.